Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 2)

Link copied
Case Copied 13 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 2) [2019] FCA 2215

File numbers: NSD 121 of 2012
NSD 837 of 2015
Judge: YATES J
Date of judgment: 11 September 2019
Catchwords: EVIDENCE – legal professional privilege - whether waiver privilege waived in certain communications
Cases cited:

Apotex Pty Ltd v Les Laboratoires Servier [2008] FCA 1466

Council of the New South Wales Bar Association v Archer (2008) 72 NSWLR 236

Ferella & Anor v Official Trustee in Bankruptcy (2010) 188 FCR 68

Macquarie Bank Limited v Arup Pty Limited [2016] FCAFC 117

Mann v Carnell (1999) 201 CLR 1

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8

Stuart v Rabobank Australia Ltd [2017] FCA 284

Date of hearing: 11 September 2019
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 28
Counsel for the Applicants/Appellants: Mr S M Nixon SC and Mr J J Hutton
Solicitor for the Applicants/Appellants: Jones Day
Counsel for the Respondents: Mr S Habib SC and Mr A R Lang
Solicitor for the Respondents: Wrays Lawyers

ORDERS

NSD 121 of 2012

BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Applicant

BRISTOL-MYERS SQUIBB COMPANY

Second Applicant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

Respondent

COMMONWEALTH OF AUSTRALIA

Other

JUDGE:

YATES J

DATE OF ORDER:

11 SEPTEMBER 2019

THE COURT ORDERS THAT:

1.The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


ORDERS

NSD 837 of 2015
BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Appellant

BRISTOL-MYERS SQUIBB COMPANY

Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

First Respondent

COMMONWEALTH OF AUSTRALIA

Other

JUDGE:

YATES J

DATE OF ORDER:

11 SEPTEMBER 2019

THE COURT ORDERS THAT:

1.The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

YATES J:

INTRODUCTION

  1. Discovery was given by Otsuka Pharmaceutical Co., Ltd (Otsuka) and Bristol-Myers Squibb Company (BMS) (together, Otsuka/BMS) in relation to applications by them to amend two pleadings styled, in each case, Response to Statement of Particulars of Claim for Damages.  The context in which the pleadings were filed is explained in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230 and Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222. In essence, Otsuka/BMS had obtained an interim injunction…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] FCA 2215
Decision Date

CaseChat Overview and Summary

The case of Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 2) was heard in the Federal Court of Australia. The dispute centred on the waiver of legal professional privilege in certain communications between Otsuka Pharmaceutical Co., Ltd, Bristol-Myers Squibb Company, and their legal counsel. The central issue before the court was whether the privilege had been waived through the disclosure of specific communications to Generic Health Pty Ltd.

The legal issues that the court had to decide involved the nature and scope of legal professional privilege, and whether the privilege was waived by the nature and content of the communications revealed in the affidavits. Specifically, the court had to determine if the privilege was waived when certain communications were disclosed to Generic Health Pty Ltd for inspection. The affidavits provided details that suggested the communications contained legal advice on the basis for the admissions, which in turn revealed the substance of the communications.

The court found that the disclosures in Mr Kerr’s affidavit were sufficient to hold that any legal professional privilege which attached to the communications in the discovered documents had been waived. The court concluded that the privilege was waived by the nature of the communications revealed, which included legal advice and the basis on which the admissions were intended to be given. As such, the court ruled that the documents should be produced to Generic Health Pty Ltd for inspection.

ORDERS:
1. The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.

Orders

Orders of the court

1. The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Although not addressed directly in the affidavit, these passages bespeak the existence of communications between Otsuka/BMS and their solicitors containing legal advice on these matters, including the basis on which the admissions were intended to be given. The substance of those communications is revealed by the affidavit as one reason why the amendments withdrawing the admissions should be allowed.CONCLUSION AND DISPOSITION The disclosures in Mr Kerr’s affidavit are sufficient for me to hold that any legal professional privilege which attached to the communications in the discovered documents has been waived. It is not necessary for me to deal with the effect of Mr Emmerig’s affidavit in this regard. The documents should be produced to Generic Health for inspection.

Ratio Decidendi

Legal Principle Established